A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF AVANAFIL (TA-1790) IN SUBJECTS WITH GENERALIZED ERECTILE DYSFUNCTION.

Trial Profile

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF AVANAFIL (TA-1790) IN SUBJECTS WITH GENERALIZED ERECTILE DYSFUNCTION.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2013

At a glance

  • Drugs Avanafil (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms REVIVE; REVIVE-G
  • Most Recent Events

    • 26 Jun 2013 Avanafil approved for treatment of erectile dysfunction in the EU based on results of the RIVIVE, REVIVE-Diabetes and REVIVE-RP, according to a VIVUS media release.
    • 28 Apr 2012 Results from this trial were used to support US FDA approval of avanafil for the treatment of erectile dysfunction.
    • 17 Jan 2012 Results published in the Journal of Sexual Medicine and a VIVUS media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top